CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on enhancing adoptive T cell therapy for metastatic cancer. It aims to improve the persistence and effectiveness of genetically modified T cells by optimizing their design and overcoming the immunosuppressive tumor environment.
Metastatic cancer remains an incurable disease in the majority of cases and thus development of novel treatment strategies is required.
Adoptive T cell therapy is a promising therapy for patients with a wide range of cancers.
This therapy involves ex vivo activation and expansion of T cells followed by infusion into patients.
Peripheral blood CD4+ and CD8+ T cells can be redirected against tumor-associated antigens (TAA) by genetically modifying them with chimeric antigen receptors (CARs).
Commo…
INSTITUT CATALA D'ONCOLOGIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, L'Hospitalet De Llobregat
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
